^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Excerpt:
    A total of 122 patients with BRAF V600 mutation–positive cancer were treated…Responses were also observed in patients with the following tumor types: anaplastic thyroid cancer (two patients), cholangiocarcinoma (one patient), salivary-duct cancer (one patient), soft-tissue sarcoma (one patient), and ovarian cancer (one patient).
    DOI:
    10.1056/NEJMoa1502309
    Trial ID:
    NCT01524978
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Excerpt:
    Of the 26 patients with BRAF V600 mutations (all V600E), objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%) with six different tumor types (two CR, 10 PR; Table 4).
    DOI:
    10.1200/JCO.2017.75.3780
    Trial ID:
    NCT02091141
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Thyroid
    Title:

    Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient Article in Thyroid 26(10) · August 2016 with 24 Reads

    Excerpt:
    Here, we present the case of an 80 year-old female patient with BRAF V600E mutation-bearing ATC and an excellent and sustained response to single agent vemurafenib.
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Mol Carcinog
    Title:

    c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

    Excerpt:
    Unlike BCPAP cells, 8505C cells presented drug resistance to PLX4032 treatment…
    DOI:
    10.1002/mc.22418